50 results about "Streptococcus agalactiae" patented technology

The invention relates to the technical field of aquaculture, in particular to nile tilapia ferritin, a preparation method and application thereof and a bacteriostatic agent. The amino acid sequence of the nile tilapia ferritin is as shown in SEQ ID No.1, and the nile tilapia ferritin inhibits streptococcus agalactiae and / or aeromonas hydrophila. The invention provides Nile tilapia ferritin, and in-vitro experiments prove that the recombinant protein can effectively inhibit proliferation of pathogenic bacteria. A further in-vivo experiment research result shows that the ferritin heavy chain (Nile tilapia ferritin) has important functions of inhibiting pathogenic bacterium proliferation and improving the survival rate of an organism, and plays an important role in immune protection of the organism.

The invention relates to the technical field of biology, in particular to an SNP (Single Nucleotide Polymorphism) marker combination for identifying tilapia streptococcus agalactiae disease resistance and application thereof. The invention discloses 11 SNP loci significantly related to streptococcus agalactiae resistance in a tilapia UTRN gene, and constructs 18 SNP marker combinations for streptococcus agalactiae resistance phenotype identification, so that the resistance phenotype identification accuracy and hereditary stability can be effectively improved. Besides, according to the SNP typing primer and method based on the # imgabs0 # MALDI-TOF mass spectrum platform, high-throughput and high-precision genetic typing can be achieved, and the SNP typing primer and method have important application value in resistance phenotype identification and assistant selective breeding.

This invention discloses a strain of Bifidobacterium animalis subspecies TRT-2A with allergy-relieving effects and its extracellular vesicle applications. The strain TRT-2A is deposited at the China Center for Type Culture Collection (CCTCC) on November 21, 2025, with accession number CCTCC NO:M 20252645. This strain is highly acid-resistant and exhibits good tolerance to artificial gastric and intestinal fluids. It effectively inhibits bacteria, particularly Streptococcus pyogenes, Streptococcus agalactiae, and / or Escherichia coli. Experimental results show that this strain can alleviate hormone-dependent dermatitis and effectively improve dermatitis symptoms such as erythema and desquamation. Furthermore, extracellular vesicles prepared using TRT-2A can effectively improve skin elasticity and reduce wrinkles. Therefore, the Bifidobacterium animalis subspecies TRT-2A of this invention has multiple functions and is worthy of further promotion and application.

The application discloses a kind of fluorescence colorimetric double-mode detection streptococcus agalactiae without aerosol pollution method, comprising the following steps: (1) strain culture and DNA extraction;(2) the combination of UDG and LAMP;(3) UDG-LAMP-CRISPR fluorescence mode detection system;(4) colorimetric mode detection system: read image RGB value in G value, G value significantly increases, and it is positive result.This patent innovatively combines UDG, LAMP, CRISPR and G4, introduces connection probe to realize "fluorescence-colorimetric" single system double-mode detection.The two detection modes of the detection platform can be freely split or combined, and can meet the needs of different detection environments.By combining UDG system and LAMP technology, aerosol pollution possibly carried in amplification process is avoided.Connection probe is introduced, CRISPR fluorescence detection is combined with G4 colorimetric detection, a detection system with "fluorescence-colorimetric" two detection modes is established, which is used for quantitative identification and cross verification of streptococcus agalactiae.

The application discloses a bocachito Nat10 antibacterial peptide, a coding sequence and use and a preparation method thereof, and relates to a method based on multiomics, a biological big data based on multiomics data of bocachito, screening and identifying an antibacterial peptide precursor gene sequence, and obtaining an amino acid sequence of the bocachito Nat10 antibacterial peptide through translation design, as shown in SEQ ID NO: 3. Through activity simulation prediction and in-vitro experiment verification, the bocachito Nat10 antibacterial peptide shows inhibitory effects on the growth activities of Streptococcus agalactiae, Salmonella enteritidis, Staphylococcus aureus, Vibrio anguillarum and Escherichia coli, especially on Staphylococcus aureus, and shows the best antibacterial effect at a concentration of 2.5 micromoles per liter. The bocachito Nat10 antibacterial peptide can be used for preparing various bactericidal preparations, including bacteriostatic agents, medicines or additives, and has good practical value and social ecological benefits.

The present application relates to the field of biotechnology, and particularly relates to a KASP molecular marker related to the resistance of tilapia to streptococcus agalactiae disease and an application thereof.Two SNP sites (SNP-1 and SNP-2) significantly associated with the resistance are screened from the intron region of EGFRX2 gene of tilapia, a typing method of the above sites is developed through KASP technology, and the correlation between the SNP-1 genotype and the resistance phenotype is verified.Further, an advantage haplotype individual with the resistance to streptococcus agalactiae disease is screened by combining the two SNP sites, and the survival rate of the individual in the challenge experiment is significantly improved.The detection kit provided by the present application can realize high-throughput and high-precision typing, is suitable for the identification of the resistance genotype of tilapia and the marker-assisted selection, provides an efficient genetic improvement tool for the disease-resistant breeding of tilapia, and is helpful to reduce the loss of breeding diseases and reduce the dependence on antibiotics.

The application discloses a recombinant strain and a preparation method thereof and application of the recombinant strain in preparation of a vaccine for Streptococcus agalactiae of tilapia, and the recombinant strain is successfully constructed by the following steps: designing an ORF4 primer, amplifying an ORF4 gene fragment from a DNA template of Streptococcus agalactiae, editing the ORF4 gene fragment into Escherichia coli by means of a CRISPR / Cas9 gene editing technology, and connecting a green fluorescent protein (GFP). The recombinant strain is subjected to immunoprotection research on the Streptococcus agalactiae of tilapia, and it is shown that the recombinant strain has a good protection effect, and can provide a solid theoretical basis and technical support for application and development of the vaccine for Streptococcus agalactiae of tilapia in the field of aquaculture.

The present application relates to the field of biotechnology, and more particularly to a SNP marker related to the level of anti-streptococcus agalactiae IgM antibody of tilapia and application thereof. The present application screens out QTLs, functional genes and key signal pathways significantly related to the level of anti-streptococcus agalactiae IgM antibody of tilapia by RNA-Seq and BSA-Seq technologies, and further identifies two SNP markers closely related to the level of anti-streptococcus agalactiae IgM antibody of tilapia, thereby providing important genetic targets and tools for molecular marker-assisted breeding of anti-streptococcus agalactiae of tilapia.

The present application relates to the field of biotechnology, and more particularly to a detection method for resistance of tilapia to streptococcosis, a KASP primer set and application. The present application identifies a key SNP site of the ABCB4 gene significantly associated with resistance of tilapia to streptococcosis by the method of population genetics, and develops a genotyping method for the SNP site by KASP technology, thereby realizing efficient evaluation of the disease-resistant trait. Experimental data show that the survival time of AA genotype individuals in the challenge test is longer than that of GA / GG genotype individuals, the proportion of resistant fish is significantly improved, and the genotype frequency distribution is strongly correlated with the disease resistance of the population. The breeding strategy based on the SNP marker can improve the overall disease resistance of the breeding population and reduce the mortality rate, thereby providing an efficient genetic improvement tool for breeding of tilapia resistant to streptococcosis, and helping to reduce the loss of breeding diseases and reduce the dependence on antibiotics.

The invention discloses a bifidobacterium animalis subsp. Lactis BT-G9 with a growth promoting function and application of the bifidobacterium animalis subsp. Lactis BT-G9, the bifidobacterium animalis subsp. Lactis BT-G9 is preserved in China Center for Type Culture Collection, the preservation date is November 20, 2025, and the preservation number is CCTCC NO: M 20252626. The brand new bifidobacterium animalis subsp. Lactis BT-G9 provided by the invention has good tolerance to gastric juice and intestinal juice, is suitable for survival in gastrointestinal tracts, can effectively inhibit bacteria, and particularly can effectively inhibit campylobacter kirscheri, streptococcus agalactiae and / or propionibacterium acnes. Experimental results show that the strain can promote animal growth and development and improve the autism, especially when the animal bifidobacterium subsp. Lactis BT-G9 and the lactobacillus acidophilus BT-C15 are combined for use, the animal bifidobacterium subsp. Lactis BT-G9 and the lactobacillus acidophilus BT-C15 have a synergistic effect, and the improvement effect on the autism can be remarkably improved. In addition, the extracellular vesicles prepared from the strain can effectively repair the skin barrier function.

The application belongs to the technical field of biological medicine, and particularly relates to application of pantothenic acid or a pharmaceutically acceptable salt thereof in preparation of a medicine for enhancing sensitivity of pathogenic bacteria to daptomycin. It is found for the first time that addition of pantothenic acid or a pharmaceutically acceptable salt thereof can improve the sensitivity of gram-positive bacteria including Staphylococcus aureus, Streptococcus agalactiae and Corynebacterium diphtheriae to daptomycin, significantly improve the bactericidal effect, and further research shows that pantothenic acid or a pharmaceutically acceptable salt thereof can promote the clearance, formation and reduction of pathogenic bacteria biofilm by daptomycin. The finding opens up a new way for overcoming antibiotic resistance and optimizing anti-infection treatment strategies.

The present application relates to the field of microbial technology, in particular to bacillus subtilis BS-1 and its application in water buffalo silage feed, the strain BS-1 of the present application has good bacteriostatic activity on escherichia coli, salmonella and streptococcus uberis, after mixing and fermenting according to a specific proportion with orange peel and cassava residue, the bacteriostatic spectrum of the obtained silage feed is significantly enhanced, which can simultaneously inhibit escherichia coli, campylobacter jejuni, salmonella, streptococcus uberis, staphylococcus aureus and streptococcus agalactiae that cause diarrhea and mastitis. In the feed, after mixing 60%-75% of orange peel and 25%-40% of cassava residue, the crude protein content of the fermentation product is significantly improved, and the fiber content is reduced. Feeding test shows that the feed can significantly improve the milk yield and milk quality of lactating water buffalo, and effectively alleviate diarrhea. The present application provides a safe, efficient and nutritious silage feed with disease prevention function.

A bacteriophage lytic enzyme and its application. The name of the bacteriophage lytic enzyme is PlyNJ3; the gene fragment encoding the lytic enzyme PlyNJ3 is amplified from streptococcus suis by PCR, and a prokaryotic expression vector plasmid pET32a-PlyNJ3 containing the PlyNJ3 gene is constructed, the recombinant plasmid is obtained by transforming DH5 alpha competent cells, and the protein is massively expressed in an escherichia coli expression system. Then, the lytic enzyme PlyNJ3 is purified by affinity purification medium, the high-efficiency expression of the lytic enzyme PlyNJ3 in vitro is realized, and the lytic effect of the lytic enzyme PlyNJ3 on different serotypes of streptococcus suis, streptococcus agalactiae and other common streptococci is verified in vitro. The bacteriophage lytic enzyme PlyNJ3 prepared by the application can selectively lyse target pathogenic bacteria, and has a good application prospect in the development of new bacteriophage drugs.

The invention discloses a lactobacillus plantarum bacteriostatic agent and application thereof, and relates to the technical field of microbial engineering. According to the lactobacillus plantarum LP2301 provided by the invention, fermentation liquor of the lactobacillus plantarum LP2301 can be used for effectively inhibiting aquatic pathogenic bacteria streptococcus agalactiae, limiting the growth of the streptococcus agalactiae, reducing the use of antibiotics, ensuring food safety and guaranteeing the health of animals and human beings by secreting metabolites such as bacteriostatic proteins and organic acids. Secondly, the invention provides an application of the lactobacillus plantarum bacteriostatic agent, and the lactobacillus plantarum LP2301 is compounded into the bacteriostatic agent; through multi-target cooperation of the cortex phellodendri extract and the rosmarinic acid, the antibacterial efficiency of single probiotics is remarkably optimized; active ingredients of cortex phellodendri directionally destroy a biological membrane barrier of streptococcus agalactiae and disintegrate an adhesion defense system of pathogenic bacteria; rosmarinic acid blocks a bacterial energy metabolism pathway synchronously, so that pathogens lose proliferative power; and exclusive bacteriocin secreted by the LP2301 accurately breaks down a cell membrane structure, so that fatal killing is realized.

The present application relates to the field of aquaculture technology, in particular to a tilapia nilotica ferritin, a preparation method and application thereof, and a bacteriostatic agent.The amino acid sequence of the tilapia nilotica ferritin is shown as SEQ ID No.1, and the tilapia nilotica ferritin can inhibit Streptococcus agalactiae and / or Aeromonas hydrophila.The present application provides the tilapia nilotica ferritin, and in-vitro experiments have proved that the recombinant protein can effectively inhibit the proliferation of pathogenic bacteria.Further in-vivo experimental results show that the ferritin heavy chain (tilapia nilotica ferritin) has the important functions of inhibiting the proliferation of pathogenic bacteria and improving the survival rate of the organism, and plays an important role in the immune protection of the organism.

The application belongs to the technical field of Chinese herbal medicines, and particularly relates to a Chinese herbal medicine composition for resisting Streptococcus agalactiae, a preparation method and application thereof. Raw materials for preparing the Chinese herbal medicine composition include cortex mali and cumin. The Chinese herbal medicine composition is easy to obtain and simple to prepare, has no chemical residues, is not prone to drug resistance, has significant bacteriostatic activity on Streptococcus agalactiae, and can be applied to the prevention and treatment of Streptococcus agalactiae disease of fish such as tilapia.

The present invention relates to molecular biology and aquaculture breeding, specifically to a method for obtaining a PRMT2 gene mutant by knocking out the gene based on CRISPR / Cas9 technology, and establishing an antibacterial strain of tilapia with a PRMT2 knockout. By knocking out this gene, a tilapia strain resistant to Streptococcus agalactiae can be obtained. Infection experiments revealed that tilapia with a PRMT2 knockout gene exhibited enhanced antibacterial activity compared to wild-type tilapia. This invention provides an important model for disease-resistant tilapia breeding and offers gene targets and new research directions for creating more disease-resistant fish strains and varieties.

The present invention relates to compositions and methods for detecting group B streptococcus (GBS, Streptococcus agalactiae) and identifying the most common genes responsible for clindamycin resistant GBS, such as ermB, ermTR, ermT, lsaC and lsaE, by multiplex real-time PCR assays.

The invention discloses a condom added with sophocarpidine hyaluronic acid lubricating liquid and a preparation method of the condom, and belongs to the technical field of condom production. The core of the method is that after matrine is dissolved, the matrine is added into hyaluronic acid lubricating liquid for the condoms, the hyaluronic acid lubricating liquid containing the matrine is prepared through stirring and mixing, the concentration of the matrine in the hyaluronic acid lubricating liquid is 7.7-25.0 mg / g, when the condoms are subjected to inner packaging, the matrine-containing lubricating agent is added into the condoms, and when the condoms are subjected to inner packaging, the matrine-containing lubricating agent is added into the condoms. And preparing the condom added with the sophocarpidine-containing hyaluronic acid lubricating liquid. According to the condom, inflammation generated after vaginal epithelial cells are stimulated by bacterial structural components is improved through matrine, and the common pathogenic bacteria such as staphylococcus aureus, escherichia coli, enterococcus faecalis and streptococcus agalactiae of vaginitis are inhibited in the using process; and the up-regulation level of NF-kB phosphorylation generated after lipopolysaccharide and peptidoglycan stimulate vaginal epithelial cells is relieved.

The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and / or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

The application discloses a tilapia Npy antibacterial peptide, a coding sequence, and a use and a preparation method thereof, and relates to the following technical scheme: based on a multi-omics method, an antibacterial peptide precursor gene sequence is screened and recognized from a tilapia multi-omics data set based on biological big data, and then the tilapia Npy antibacterial peptide amino acid sequence is obtained through translation design, as shown in SEQ ID NO: 3; through activity simulation prediction and in-vitro experiment verification, the tilapia Npy antibacterial peptide shows inhibitory activity to gram-positive streptococcus agalactiae, staphylococcus aureus and gram-negative escherichia coli, especially to streptococcus agalactiae and staphylococcus aureus, and shows good antibacterial effect at a low concentration (2.5 μmol / L), and can be used for preparing antibacterial products, including preparation of an antibacterial agent, preparation of a medicine or preparation of an additive, and has good practical value and social ecological benefits.

The present application relates to oligosaccharide composition and its use. The present application particularly relates to the use of oligosaccharide composition in the preparation of products for preventing and / or treating aquaculture diseases caused by Vibrio parahaemolyticus, Vibrio harveyi and Streptococcus agalactiae, wherein the oligosaccharide composition is obtained by degrading polygalacturonan or pectin by a polygalacturonase as shown in SEQ ID No: 1, under the conditions of a polygalacturonase concentration of 0.045 mg / mL to 0.055 mg / mL, a polygalacturonan concentration of 7% to 9%, and a degradation time of 12 hours to 20 hours. The present application also relates to the use of oligosaccharide composition in aquaculture. The oligosaccharide composition of the present application has good bacteriostatic effect and disease prevention and control effect in aquaculture.

The invention belongs to the technical field of antibiotic enzymes, and relates to a recombinant antibiotic enzyme PlyTC37 as well as a coding gene and application thereof. The amino acid sequence of the recombinant antibiotic enzyme PlyTC37 is as shown in SEQ ID NO. 1, and the coding nucleotide sequence of the recombinant antibiotic enzyme PlyTC37 is as shown in SEQ ID NO. 2. The recombinant antibiotic enzyme PlyTC37 disclosed by the invention has a wider bactericidal spectrum, so that the recombinant antibiotic enzyme PlyTC37 has a killing effect on gram-negative bacteria such as acinetobacter baumannii, klebsiella pneumoniae, escherichia coli, salmonella and pseudomonas aeruginosa and gram-positive bacteria such as staphylococcus aureus, streptococcus agalactiae and streptococcus hemolyticus, the MIC value of the recombinant antibiotic enzyme PlyTC37 to acinetobacter baumannii, klebsiella pneumoniae, escherichia coli, salmonella and pseudomonas aeruginosa is about 20 [mu] g / ml. Meanwhile, the recombinant antibiotic enzyme PlyTC37 enables the load of acinetobacter baumannii, klebsiella pneumoniae, escherichia coli, salmonella and pseudomonas aeruginosa to be reduced by 4-5 logarithmic units in the presence of NaCl with physiological concentration, so that the clinical application prospect of the recombinant antibiotic enzyme PlyTC37 is remarkably improved.

The present invention relates to oligosaccharide compositions and uses thereof. The invention particularly relates to application of an oligosaccharide composition in preparation of products for preventing and / or treating aquaculture diseases caused by vibrio parahaemolyticus, vibrio harveyi and streptococcus agalactiae, and the oligosaccharide composition is obtained by degrading polygalacturonic acid or pectin by polygalacturonase shown as SEQ ID No: 1. The degradation conditions are as follows: the concentration of the polygalacturonase is 0.045 mg / mL to 0.055 mg / mL, the concentration of the polygalacturonic acid is 7% to 9%, and the degradation time is 12 hours to 20 hours. The invention also relates to the use of the oligosaccharide composition in aquaculture. The oligosaccharide composition disclosed by the invention has good effects of inhibiting bacteria and preventing and treating aquaculture diseases.

The present invention relates to the development of a microencapsulated vaccine containing inactivated Streptococcus agalactiae, together with the adjuvants beta glucan and mineral oil, to be administered orally to fish together with feed in pelletised form or coated with the vaccine. In addition, the invention relates to the use of this vaccine to immunise fish, more specifically Nile tilapia (Oreochromis niloticus) to activate both innate and adaptive (humoral and cellular) intestinal mucosal immunity and protect tilapia against streptococcosis. Such a vaccine can be applied in intensive fishing production systems, with the aim of reducing fish mortality, reducing the use of antimicrobials and not causing environmental damage, being easy to administer and control, reducing fish handling, and being suitable for immunising large numbers of animals at the same time without stress and at low cost.

The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B Streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and / or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

The invention relates to the technical field of disease prevention and control of aquatic animals, and particularly discloses a fermented traditional Chinese medicine composition for resisting tilapia streptococcus agalactiae and a preparation method and application thereof.The fermented traditional Chinese medicine composition is obtained by fermenting the following traditional Chinese medicine raw materials in parts by weight: 1.2-5 parts of radix scutellariae, 0.5-2.5 parts of fructus chebulae and 0.5-1 part of radix et rhizoma rhei. The preparation method comprises the following steps: adding the traditional Chinese medicine raw materials into a fermentation culture medium in parts by weight, then inoculating a mixed fermentation bacterial solution, and carrying out fermentation culture in an environment of 35-39 DEG C, so as to obtain the fermented traditional Chinese medicine composition for resisting tilapia streptococcus agalactiae after fermentation is completed. The proper traditional Chinese medicine raw material combination is selected and fermented, and the survival rate of the tilapia infected with streptococcus agalactiae can be remarkably increased through test evaluation.

The invention provides a method for purifying capsular polysaccharide of streptococcus agalactiae. According to the method, CTAB (cetyltrimethyl ammonium bromide) and impurities are removed through ethanol with different concentrations under the condition that salt ions (sodium ions or calcium ions) or not exist. In the whole process flow, phenol reagents which are high in harm to human bodies and environment and high in safety risk are prevented from being used, so that the safety of operators is effectively protected on the basis of ensuring the purification quality, and the damage of phenol to the environment is avoided. The capsular polysaccharide prepared by the invention has the advantages of high purity, low content of impurities such as endotoxin and nucleic acid, simplified steps, simple and controllable operation process, smaller batch-to-batch difference and better process stability, and is suitable for large-scale production.

The invention discloses lactobacillus acidophilus BT-C15 with inflammation relieving and mucosal barrier repairing functions and application of the lactobacillus acidophilus BT-C15, the lactobacillus acidophilus BT-C15 is preserved in the China Center for Type Culture Collection, the preservation date is November 20, 2025, and the preservation number is CCTCC NO: M 20252625. The invention provides a brand new lactobacillus acidophilus BT-C15 which mainly has the effects of relieving inflammation and whitening the skin. The lactobacillus acidophilus BT-C15 has good tolerance to gastric juice and intestinal juice, is high in cell adhesion capacity, is suitable for survival in gastrointestinal tracts, can effectively inhibit bacteria, and particularly can effectively inhibit campylobacter Korotkoff, streptococcus agalactiae and / or propionibacterium acnes. Experimental results show that the strain can improve colitis, fade spots, whiten skin and improve autism, especially when the lactobacillus acidophilus BT-C15 and the bifidobacterium animalis subsp. Lactis BT-G9 are used in a combined mode, the lactobacillus acidophilus BT-C15 and the bifidobacterium animalis subsp. Lactis BT-G9 have a synergistic effect, and the improvement effect on the autism can be remarkably improved.

The present application relates to the field of biotechnology, and particularly relates to SNP marker combination for identifying resistance to streptococcus agalactiae disease of tilapia and application thereof. The present application discloses 11 SNP sites in UTRN gene of tilapia which are significantly related to resistance to streptococcus agalactiae disease, and constructs 18 SNP marker combinations for identifying resistance phenotype of streptococcus agalactiae disease, which can effectively improve the accuracy and genetic stability of resistance phenotype identification. In addition, the SNP typing primer and method based on MALDI-TOF mass spectrometry platform provided by the present application can realize high-throughput and high-precision genotyping, and has important application value in resistance phenotype identification and assisted selection breeding.